Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 8.96B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -303.27M |
| Shares Out | 27.85M |
| EPS (ttm) | -13.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,136 |
| Open | 339.94 |
| Previous Close | 330.99 |
| Day's Range | 319.40 - 344.00 |
| 52-Week Range | 34.89 - 356.00 |
| Beta | 2.97 |
| Analysts | Strong Buy |
| Price Target | 572.13 (+77.87%) |
| Earnings Date | May 8, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in N... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $572.13, which is an increase of 77.87% from the latest price.
News
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully int...
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial
Praxis said elsunersen demonstrated a placebo-adjusted seizure reduction from baseline of 77% (p=0.015) in pediatric patients with SCN2A developmental and epileptic encephalopathy.
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observe...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, t...
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sys...
Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference
NDA for Ulyxa submitted with standard review to optimize economic and regulatory outcomes, with launch preparations including disease awareness, specialty pharmacy, and a large sales force. Pipeline progress includes relumitragene for rare epilepsy, vormetragine for focal seizures, and ongoing phase III for elsunersen.
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.
Praxis Precision Medicines Earnings Call Transcript: Q4 2025
Major clinical and regulatory milestones achieved in 2025, including two NDA submissions and strong pivotal data across the CNS portfolio. Financial position strengthened with $1.5B in cash, supporting multiple commercial launches and pipeline progress into 2028.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. ...
Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Significant unmet need in essential tremor and epilepsy is being addressed with new therapies, with two NDAs on track for mid-February filing. Commercial strategy includes robust sales force, targeted outreach, and pricing in the $40,000–$60,000 range. Cash reserves support launches into 2028.
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders
SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medic...
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen
Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next
Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patient...
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting...
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026
Praxis Precision Medicines Transcript: Fireside Chat
The discussion provided an in-depth review of the Essential Three program's statistical rigor, addressing concerns about endpoint changes, missing data, and sensitivity analyses. Robustness was demonstrated through multiple methods, with consistent, highly significant results across primary and secondary endpoints.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...